BMS/Janssen Will Begin Phase III For Factor XIa Inhibitor Milvexian By Year-End
Phase II Showed Potential Beyond Prior Anticoagulants
Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.
